ClinicalTrials.gg
CompletedNCT01048788Updated Apr 11, 2016Results posted

A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg

A Phase 3 interventional study of OPC-41061 in Cirrhosis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-04-11.

Primary conditionFibrosis(the registry's first term)UnverifiedIs this wrong?Fibrosis is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Study summary

OPC-41061 will be orally administered at 7.5 mg/day for 7 days to cirrhosis patients with ascites despite having received conventional diuretic therapy. Based on the change in body weight, on Day 7 it will be decided whether to continue administration at the same dose or to increase the dose, and then OPC-41061 will be orally administered for an additional 7 days at either 7.5 mg/day or, if diuretic effect for the initial 7-day administration is insufficient, at an increased dose of 15 mg/day. Plasma drug level, efficacy, and safety of OPC-41061 by 14-day repeated administration will be investigated.

02

Conditions studied

  • Cirrhosis

Browse trials for

Keywords

  • Cirrhosis
  • ascites
  • Tolvaptan
  • OPC-41061
03

In context

Fibrosis Unverified

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

This study's enrollment of 51 is below the median of 63 across 841 interventional studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients judged as having cirrhosis* based on previous imaging diagnosis

    • Definition of cirrhosis includes patients with collateral circulation due to chronic hepatic impairment
  • Patients with ascites in whom the dose of existing diuretics cannot be increased due to risk of adverse drug reactions such as electrolyte abnormalities, or in whom sufficient therapeutic effect cannot be obtained with existing diuretics
  • Patients who have been receiving oral combination therapy with a loop diuretic and an anti-aldosterone agent from at least 7 days prior to receipt of , with a dose combination of either loop diuretic equivalent to furosemide 40 mg/day or higher plus spironolactone 25 mg/day or higher, or loop diuretic equivalent to furosemide 20 mg/day or higher plus spironolactone 50 mg/day or higher
  • Patients who are hospitalized or who can be hospitalized for the trial
  • Patients capable of giving informed consent
  • Patients who, together with their partner, agree to use an appropriate method of until 4 weeks after the final trial drug administration

Exclusion criteria

Exclusion Criteria:

  • Patients with any of the following complications or symptoms:
  • Hepatic encephalopathy (hepatic coma of grade 2 or higher)
  • Hepatocellular carcinoma with imaging-diagnosed vascular infiltration into trunk or primary branch of portal vein, inferior vena cava, or trunk of hepatic vein
  • Endoscopic findings from screening examination or from within 30 days prior to screening examination indicating the need for new therapy for esophageal or gastric varices during the trial period
  • Repeated hemorrhoidal bleeding due to rectal varicose veins within 30 days prior to
  • Heart failure ( Class III or IV)
  • Anuria
  • Impaired urination due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
  • Patients with a history of any of the following disorders:
  • Cerebrovascular disorder within 30 days prior to informed consent
  • or idiosyncratic reaction to benzazepine derivatives (such as mozavaptan hydrochloride or benazepril hydrochloride)
  • Morbidly obese patients with a (BMI: body weight (kg)/height (m)2) exceeding 35
  • Patients with sitting systolic blood pressure lower than 90 mmHg
  • Patients with any of following abnormal clinical laboratory values at time of the screening examination: lower than 8.0 g/dL, total higher than 4.0 mg/dL, serum creatinine higher than 2.0 mg/dL, serum sodium higher than 147 mEq/L, or serum potassium higher than 5.5 mEq/L
  • Patients who are unable to take oral medication
  • Female patients who are pregnant, possibly pregnant, or breast-feeding, or who are planning to become pregnant
  • Patients who have used albumin preparations (therapeutic agents for hypoalbuminemia) or blood products containing albumin from within 7 days prior to informed consent
  • Patients who received any drug other than OPC-41061 within 30 days prior to informed consent
  • Patients who have previously received OPC-41061
  • Any patient who, in the opinion of the principle investigator or subinvestigator, is inappropriate for participation in the trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    OPC

    Drug: OPC-41061

Interventions

  • OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.

06

What researchers measure

Primary outcomes

  1. Body Weight

    Changes in body weight from baseline at the end of administration

    Time frame: Baseline, Day 14 or end of administration

07

Results

Posted Mar 4, 2014

Participant flow

Participant flow — Overall Study
MilestoneDiscontinued/Terminated Before Day8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/Day
Started83013
Completed32811
Not completed522
Withdrew: Adverse event511
Withdrew: Lack of efficacy001
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryBody Weight

Changes in body weight from baseline at the end of administration

Time frame:
Baseline, Day 14 or end of administration
Reported as:
Mean · Kg
Body Weight
KgDiscontitued/Terminated Before Day 8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/Day
Body Weight-0.76 ± 0.93-2.97 ± 2.57-0.05 ± 2.30

Adverse events

Collected over 14 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Discontinued/Terminated Before Day8—3/8 (37.5%)7/8 (87.5%)
Continued Administration at 7.5 mg/Day—3/30 (10%)22/30 (73.3%)
Dose Escalation to 15 mg/Day—2/13 (15.4%)7/13 (53.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventDiscontinued/Terminated Before Day8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/Day
Positional VertigoEar and labyrinth disorders1/80/300/13
Hernia ObstructiveGeneral disorders1/80/300/13
Muscular WeaknessMusculoskeletal and connective tissue disorders1/80/300/13
Diabetic NeuropathyNervous system disorders1/80/300/13
Hepatic EncephalopathyNervous system disorders1/81/301/13
Polyneuropathy AlcoholicNervous system disorders1/80/300/13
Peritonitis BacterialInfections and infestations0/80/301/13
SepticaemiaInfections and infestations0/80/301/13
AscitesGastrointestinal disorders0/81/300/13
Oesophageal Varices HaemorrhageGastrointestinal disorders0/81/300/13
Most frequent other events
Showing 10 of 18
Most frequent other events
EventDiscontinued/Terminated Before Day8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/Day
ThirstGeneral disorders1/810/301/13
MalaiseGeneral disorders0/80/302/13
PyrexiaGeneral disorders1/83/302/13
HeadacheNervous system disorders0/80/302/13
InsomniaPsychiatric disorders0/84/302/13
ConstipationGastrointestinal disorders1/84/300/13
Blood Creatinine IncreasedInvestigations0/84/300/13
Abdominal DistensionGastrointestinal disorders1/81/301/13
Procedural PainInjury, poisoning and procedural complications1/80/300/13
Blood Pressure DecreasedInvestigations1/83/301/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Discontinued/Terminated Before Day8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/DayTotal
Mean66.3 ± 6.863.9 ± 8.261.0 ± 11.463.5 ± 8.9
Age, Categorical
Age, Categorical(Participants)Discontinued/Terminated Before Day8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/DayTotal
<=18 years0000
Between 18 and 65 years414826
>=65 years416525
Sex: Female, Male
Sex: Female, Male(Participants)Discontinued/Terminated Before Day8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/DayTotal
Female29415
Male621936
Region of Enrollment
Region of Enrollment(participants)Discontinued/Terminated Before Day8Continued Administration at 7.5 mg/DayDose Escalation to 15 mg/DayTotal
Japan8301351
08

Study locations

6 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2010
First posted
Jan 14, 2010
Start
Dec 2009
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Mar 4, 2014
Last update
Apr 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01048788
Responsible party
Sponsor
First posted
Jan 14, 2010
Start date
Dec 2009
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Mar 4, 2014
Last update
Apr 11, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion